VSIR and cancer: The upregulation of VISTA that emerged in PCa patients treated with ipilimumab raises a question of how it fits in with the timeline in cancer development 116: does it emerge as a backup checkpoint when other checkpoints fail to protect the tumor, or does it have other functions that directly fuel cancer growth and metastasis?